Document:

Exhibit 4.12

 

NEITHER THIS NOTE, NOR THE SHARES OF
COMMON STOCK FOR WHICH IT IS CONVERTIBLE, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR APPLICABLE STATE SECURITIES LAWS AND NEITHER MAY BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER
THE ACT AND SUCH LAWS OR (1) REGISTRATION UNDER APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED AND (2) AN OPINION OF COUNSEL
SATISFACTORY TO THE MAKER IS FURNISHED TO THE MAKER TO THE EFFECT THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED.

 

Payment
of this Subordinated CONVERTIBLE Promissory Note and the rights and remedies of the holder hereof are subject to the terms and
conditions of a Subordination Agreement dated as of APRIL 17, 2017 between the Payee (as defined below) and HORIZON Credit II LLC
(as the same may be amended and/or restated, the “Subordination Agreement”). Any successors and assigns of the holder
of this Subordinated ONVERTIBLE Promissory Note shall be subject to and bound by the terms and conditions of such Subordination
Agreement. A copy of such Subordination Agreement may be obtained, upon written request of any holder of this Subordinated CONVERTIBLE
Promissory Note from THE MAKER.

 

Subordinated
Convertible Promissory Note

 

	$[________.00]	Waltham, Massachusetts	April 17, 2017

 

1.            For
Value Received, the undersigned, Interleukin
Genetics, Inc., a Delaware
Corporation (the “Maker”), hereby promises to pay to [__________](the
“Payee”), in lawful money of the United States of America, the principal amount of
[___________] Dollars ($[_____].00)], together with interest on the unpaid balance of said principal amount from time
to time remaining outstanding, from the date hereof until repayment thereof in full, in like money, at said office, or the conversion
thereof in full, at a rate per annum equal to the Interest Rate (as defined below).

 

This subordinated convertible promissory
note (the “Note”) is issued by the Maker pursuant to that certain Subscription Agreement dated as of
April 17, 2017 (the “Subscription Agreement”) entered into among the Maker, the Payee and the other purchasers
of the other subordinated convertible promissory note(s) of the Maker issued on or about April 17, 2017 (the “Issue
Date”) pursuant to the Subscription Agreement (collectively with this Note, the “Notes”).

 

2.            Maturity.
If not sooner paid or converted according to the terms hereof, the outstanding principal amount plus all accrued and unpaid interest
thereon shall be due and payable in full upon written demand to the Maker (received at least five (5) days before such payments
shall be made by the Maker) by the holders of Notes representing at least fifty percent (50%) of the aggregate principal amount
of the Notes then outstanding (the “Requisite Holders”) on or after January 1, 2022 (the “Maturity
Date”). Notwithstanding the foregoing, if the Maker closes a Change of Control on or before the Maturity Date, and
this Note is not converted under Section 5(c) in connection with such Change of Control, then the outstanding principal amount
plus all accrued and unpaid interest thereon shall be due and payable in full upon the closing of such Change of Control.

 

    	 	-1-	 

     

    

 

3.            Interest.
This Note shall bear interest at the rate of 8% per annum, simple interest, from the date of issuance until paid or converted in
full (the “Interest Rate”). Interest on this Note shall be computed on the basis of a 365-day year for
the actual number of days (including the first day but excluding the last day) occurring in the period for which such interest
is payable. Interest shall be due and payable at the Maturity Date.

 

4.            Prepayment.
Subject to the terms and conditions of the Subordination Agreement, the Maker may prepay any of the principal amount of this Note
upon at least ten (10) days advance written notice to the Payee (a “Notice of Prepayment”) by the Maker
of the date of prepayment (the “Prepayment Date”). Any prepayment shall be accompanied by the interest
accrued on the prepaid principal amount through and including the Prepayment Date.

 

5.            Conversion.

 

(a)          Mandatory
Conversion. Upon the Closing of the Qualified Financing (as defined below) on or before the Maturity Date, and simultaneously
with the Closing of the Qualified Financing, the unpaid principal amount and accrued interest outstanding under this Note shall
automatically (without payment of any additional consideration and without action on the part of the Payee) convert in whole (but
not in part) into fully paid and nonassessable shares of Common Stock, par value $0.001 per share, of the Maker (the “Common
Stock”). The total number of shares of Common Stock issuable upon conversion of this Note pursuant to this Section
5(a) shall be determined by dividing (i) the then outstanding principal amount and accrued interest under this Note by (ii) a conversion
price equal to (A) eighty percent (80%) multiplied by (B) the lowest price per share of the Common Stock paid by investors to the
Company in such Qualified Financing. No fractional shares shall be issued and the value of any fractional share shall be paid by
the Maker to the Payee in cash. In connection with the conversion of this Note under this Section 5(a), the Payee will be granted
the same registration rights with respect to the shares of Common Stock issued upon such conversion as granted to the purchasers
of Common Stock in the Qualified Financing, if any.

 

(b)          Optional
Conversion. During the period commencing on the Issue Date and expiring on the earlier of the Closing of the Qualified Financing
and the Maturity Date, the holder of this Note shall have the right to convert the then outstanding principal amount of this Note
(or any portion thereof), together with accrued interest thereon, into shares of Common Stock. If the Company provides a Notice
of Prepayment to the holder of this Note, the holder of this Note shall have the right to convert the then outstanding principal
amount of this Note (or any portion thereof), together with accrued interest thereon, into shares of Common Stock until 5:00 p.m.,
Eastern Time, on the day immediately preceding the Prepayment Date. The total number of shares of Common Stock issuable upon conversion
of this Note pursuant to this Section 5(b) shall be determined by dividing (i) the then outstanding principal amount of this Note
(or any portion thereof), together with accrued interest thereon by (ii) a conversion price equal to $0.125256. No fractional shares
shall be issued and the value of any fractional share shall be paid by the Maker to the Payee in cash.

 

    	 	-2-	 

     

    

 

(c)          Conversion
Upon a Change of Control. If a Change of Control closes before the Closing of the Qualified Financing and on or before the
Maturity Date, then upon the written election of the Requisite Holders, the unpaid principal amount and accrued interest outstanding
under this Note shall automatically (without payment of any additional consideration and without action on the part of the Payee)
convert in whole (but not in part) into fully paid and nonassessable shares of Common Stock immediately before the closing of the
Change of Control The total number of shares of Common Stock issuable upon conversion of this Note pursuant to this Section 5(c)
shall be determined by dividing (i) the then outstanding principal amount and accrued interest under this Note by (ii) a conversion
price equal to (A) eighty percent (80%) multiplied by (B) the price per share of Common Stock in such Change of Control. No fractional
shares shall be issued and the value of any fractional share shall be paid by the Maker to the Payee in cash. In connection with
the conversion of this Note under this Section 5(c), the Payee will be granted the same registration rights with respect to the
shares of Common Stock issued upon such conversion as granted to similarly situated holders of Common Stock in the Change of Control,
if any.

 

The Company shall provide
the Payee with not less than twenty (20) days prior written notice of a Change of Control (including the material terms of the
proposed Change of Control) (to the extent the Maker has notice of such Change of Control) and the Requisite Holders may elect
in writing at any time before the fifth (5th) day before the closing of such Change of Control to convert the indebtedness
represented by this Note into shares of Common Stock pursuant to this Section 5(c) immediately prior, and subject to, the closing
of the Change of Control.

 

(d)          Mechanics
and Effect of Conversion. Upon conversion of this Note pursuant to this Section 5, the Payee shall surrender this Note, duly
endorsed, to the Maker; provided, however, that failure by the Payee to so surrender this Note shall not prevent
the conversion of, and cancellation of, this Note in accordance with this Section 5. At its expense, the Maker shall, as soon as
practicable after surrender of the duly endorsed Note in accordance with this Section 5, issue and deliver to the Payee a certificate
or certificates for the number of shares of Common Stock to which the Payee shall be entitled upon such conversion (bearing such
legends as are required by applicable state and federal securities laws in the opinion of counsel to the Maker), together with
a check payable to the Payee for any cash amounts payable for fractional shares, if applicable. Upon conversion of this Note, the
Maker shall be released from all its obligations and liabilities under this Note.

 

6.            Events
of Default. The occurrence of any of the following events shall constitute an “Event of Default”
hereunder:

 

(a)          the
Maker shall fail to pay timely when due, the principal of, or accrued unpaid interest on, the Notes or any other of the obligations
hereunder or thereunder; or

 

    	 	-3-	 

     

    

 

(b)          the
Maker shall violate, or be in material breach of, any of the representations or warranties under the Subscription Agreement or
the Notes, or shall violate, or be in material breach of, the Subscription Agreement or the Notes and such violation or breach
continues for thirty (30) days after the Maker receives written notice of such violation or breach from the Payee; or

 

(c)          the
Maker shall (i) voluntarily terminate operations or apply for or consent to the appointment of, or the taking of possession by,
a receiver, custodian, trustee or liquidator of the Maker or of all or a substantial part of the assets of the Maker, (ii) admit
in writing its inability to pay debts as the debts become due, (iii) make a general assignment for the benefit of its creditors,
(iv) commence a voluntary case under the Federal Bankruptcy Code (as now or hereafter in effect), (v) file a petition seeking to
take advantage of any other law relating to bankruptcy, insolvency, reorganization, winding-up, or composition or adjustment of
debts, (vi) fail to controvert in a timely and appropriate manner, or acquiesce in writing to, any petition filed against it in
an involuntary case under the Federal Bankruptcy Code or applicable state bankruptcy laws or (vii) take any corporate action for
the purpose of effecting any of the foregoing; or

 

(d)          without
the Maker’s application, approval or consent, a proceeding shall be commenced, in any court of competent jurisdiction, seeking
in respect of the Maker: the liquidation, reorganization, dissolution, winding-up, or composition or readjustment of debt, the
appointment of a trustee, receiver, liquidator or the like relief in respect of the Maker or all or any substantial part of the
assets of the Maker, or other like relief in respect of the Maker under any law relating to bankruptcy, insolvency, reorganization,
winding-up, or composition or adjustment of debts; and, if the proceeding is being contested in good faith by the Maker, the same
shall continue undismissed, or unstayed and in effect for any period of ninety (90) consecutive days, or an order for relief against
the Maker shall be entered in any case under the Federal Bankruptcy Code or applicable bankruptcy laws.

 

Upon the occurrence of an Event of Default,
the Requisite Holders, at their option, upon written notice to the Maker, may declare the unpaid principal portion of this Note
(and the other Notes) to be forthwith due and payable, whereupon the said portion of this Note (and the other Notes) and all accrued,
earned and unpaid interest hereon (and thereon) shall become immediately due and payable by the Maker without demand, presentment
for payment, notice of non-payment, protest, notice of protest, notice of intent to accelerate maturity, or any other notice of
any kind (other than notice of acceleration of maturity) to the Maker, or any other person liable hereon or with respect hereto,
all of which are hereby expressly waived by the Maker and each other person liable hereon or with respect hereto, anything contained
herein or in any other documents or instruments to the contrary notwithstanding.

 

7.            Limitation
on Interest. The Maker and the Payee and the holder of this Note specifically intend and agree to limit contractually the amount
of interest payable under this Note to the maximum amount of interest lawfully permitted to be charged under applicable law. Therefore,
none of the terms of this Note shall ever be construed to create a contract to pay interest at a rate in excess of the maximum
rate of permitted to be charged under applicable law, and neither the Maker nor any other party liable or to become liable hereunder
shall ever be liable for interest in excess of the amount determined at such maximum rate, and the provisions of this Section 7
shall control over any contrary provision of this Note.

 

    	 	-4-	 

     

    

 

8.          Certain
Waivers. The Maker waives demand, presentment for payment, notice of non-payment, protest, notice of protest, notice of intent
to accelerate maturity, notice of acceleration of maturity and all other notice, filing of suit and diligence in collecting this
Note and further agrees that it will not be necessary for any holder hereof, to enforce payment of this Note, to consent to any
one or more extensions or postponements of time of payment of this Note on any terms or any other indulgences with respect hereto,
without notice thereof to any of them.

 

9.          Replacement
of Note. Upon receipt of the Maker of evidence reasonably satisfactory to it of ownership of and the loss, theft, destruction
or mutilation of this Note, and (a) in the case of loss, theft or destruction of indemnity reasonably satisfactory to it; provided,
however, that if the holder of this Note is, or is a nominee for, the Payee or any other institutional investor, such person’s
own unsecured agreement of indemnity shall be deemed to be satisfactory, or (b) in the case of mutilation, upon surrender and cancellation
this Note, the Maker, at its own expense, shall execute and deliver a new Note, dated and bearing interest from the date to which
interest shall have been paid on this lost, stolen, destroyed or mutilated Note or dated the date of this lost, stolen, destroyed
or mutilated Note if no interest shall have been paid hereon.

 

10.         Governing
Law. This Note and all rights and obligations of the parties hereunder shall be governed by and be construed and enforced in
accordance with the laws of the Commonwealth of Massachusetts without regard to Massachusetts or federal principles of conflict
of laws.

 

11.          Defined
Terms. The terms set forth below shall have the meanings assigned to such terms as used in this Note:

 

“Change
of Control” means (a) the sale, lease, exchange, conveyance or other disposition of all or substantially all of the
Maker’s property or business, or (b) the Maker’s merger into or consolidation with any other corporation or entity
(other than a wholly-owned subsidiary of the Maker), or any transaction (including a merger or other reorganization) or series
of related transactions, in which more than 50% of the voting power of the Maker’s capital stock is disposed of.

 

“Closing
of the Qualified Financing” means the closing of the particular round of the Qualified Financing that results in
the Proceeds (as defined below) to the Maker of all rounds of the Qualified Financing closed to that date being at least $5.0 million.

 

“Qualified
Financing” means the Maker’s next Common Stock financing, whether in a single transaction or series of related
transactions, whether a public or private financing, yielding aggregate cash proceeds to the Maker (inclusive of amounts converted
under the Notes or other outstanding indebtedness of the Maker) (such amount, the “Proceeds”) of at least
$5.0 million.

 

    	 	-5-	 

     

    

 

12.         Amendments
and Waivers. This Note may be amended only with the written consent of the Maker and the Requisite Holders. Any amendment or
waiver effected in accordance with this Section 12 shall be binding upon the Maker and all holders of the Notes.

 

13.        Stockholders,
Officers and Directors Not Liable. In no event shall any stockholder, officer or director of the Maker be liable for any amounts
due or payable pursuant to this Note.

 

14.         Subordination.
This Note shall be subordinated to all amounts payable under that certain Venture Loan and Security Agreement dated as of December
23, 2014 between the Maker and Horizon Technology Finance Corporation (as the same may be amended and/or restated) pursuant to
the terms of the Subordination Agreement.

 

[END OF TEXT]

 

    	 	-6-	 

     

    

 

Executed and delivered
as an instrument under seal in Waltham, Massachusetts, on and as of the date first above written.

 

	 	THE MAKER:
	 	 
	 	INTERLEUKIN GENETICS, INC.
	 	 
	 	By: 	 
	 	Name:
	 	Title:
	 	 
	 	THE PAYEE:
	 	 
	 	[________________________]
	 	 
	 	By:  	 
	 	Name:
	 	Title:Exhibit
10.18.3

 

SECOND amendment
of VENTURE LOAN AND SECURITY AGREEMENT

 

This SECOND AMENDMENT OF VENTURE LOAN AND
SECURITY AGREEMENT (this “Agreement”), dated as of April 17, 2017, is entered into by and among INTERLEUKIN
GENETICS, INC. (“Borrower”) and HORIZON CREDIT II LLC, as assignee
of Horizon Technology Finance Corporation (“Lender”).

 

RECITALS

 

A.           Borrower
and Lender are parties to a certain Venture Loan and Security Agreement dated as of December 23, 2014, as amended to date (as so
amended, the “Loan Agreement”) pursuant to which Lender, among other things, has provided a loan to Borrower
(“Loan A”) as evidenced by a certain Secured Promissory Note (Loan A) executed by Borrower in favor of Lender,
amended and restated as of August 1, 2016, in the original principal amount of Five Million Dollars ($5,000,000.00) (“Loan
A Note”).

 

B.           Borrower
has now requested that Lender agree to amend the Loan Agreement to revise the repayment schedule of Loan A.

 

C.           Lender
is willing to grant such request, but only to the extent, and in accordance with the terms, and subject to the conditions, set
forth herein.

 

agreement

 

NOW, THEREFORE, in consideration of the
above recitals and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower
and Lender hereby agree as follows:

 

1.            Definitions;
Interpretation. Unless otherwise defined herein, all capitalized terms used herein and defined in the Loan Agreement shall
have the respective meanings given to those terms in the Loan Agreement. Other rules of construction set forth in the Loan Agreement,
to the extent not inconsistent with this Agreement, apply to this Agreement and are hereby incorporated by reference.

 

2.            Confirmation.
Borrower hereby acknowledges and agrees that: (i) the Loan Agreement sets forth the legal, valid, binding and continuing obligations
of Borrower to Lender, (ii) the Obligations to Lender under the Loan Agreement are secured by validly perfected security interests
in all assets of Borrower, including Borrower’s Intellectual Property, and (iii) Borrower has no cause of action, claim,
defense or set-off against the Lender in any way regarding or relating to the Loan Agreement or Lender’s actions thereunder
and to the extent any such cause of action, claim, defense or set-off ever existed, it is waived and Lender is released from any
claims of Borrower. Borrower represents and warrants that no Default or Event of Default has occurred under the Loan Agreement.

 

3.            Amended
and Restated Note. The Loan A Note is hereby amended and restated in its entirety as set forth in Exhibit A annexed
hereto and made a part hereof (the “Second Amended and Restated Note”).

 

    	 	1	 

     

    

 

4.             Conditions
to Effectiveness. Lender consents and agreement herein is expressly conditioned on each of the following:

 

		(a)	Borrower executing and delivering to Lender an executed
copy of this Agreement;

 

		(b)	Borrower executing and delivering to Lender an executed
copy of the Second Amended and Restated Note;

 

		(c)	Borrower executing and delivering to Lender a warrant
to purchase Borrower’s Equity Securities in the form attached hereto as Exhibit B;

 

		(d)	Borrower providing Lender with evidence reasonably
satisfactory to Lender that Borrower has received cash proceeds of not less than One Million Dollars ($1,000,000) from the issuance
of subordinated promissory notes, which notes shall be subordinated to the Note pursuant to the terms of a subordination agreement
in form and substance acceptable to Lender;

 

		(e)	Lender’s receipt of a fully executed subordination
agreement with respect to the subordinated promissory notes issued by Borrower in satisfaction of the condition set forth in Section
4(d) above; and

 

		(f)	Borrower’s payment of Lender’s in-house
legal expenses in the amount of Five Thousand Dollars ($5,000) incurred in connection with the drafting, negotiation and execution
of this Agreement.

 

5.             Effect
of Agreement. On and after the date hereof, each reference to the Loan Agreement in the Loan Agreement or in any other document
shall mean the Loan Agreement as amended by this Agreement. Except as expressly provided hereunder, the execution, delivery and
effectiveness of this Agreement shall not operate as a waiver of any right, power, or remedy of Lender, nor constitute a waiver
of any provision of the Loan Agreement. Except to the limited extent expressly provided herein, nothing contained herein shall,
or shall be construed to (nor shall Borrower ever argue to the contrary) (i) modify the Loan Agreement or any other Loan Document
(ii) modify, waive, impair, or affect any of the covenants, agreements, terms, and conditions thereof, or (iii) waive the due keeping,
observance and/or performance thereof, each of which is hereby ratified and confirmed by Borrower. Except as amended above, the
Loan Agreement remains in full force and effect.

 

6.            Representations
and Warranties. Borrower represents and warrants to Lender as follows:

 

		(a)	All representations and warranties of Borrower in this
Agreement and the Loan Agreement are true and correct in all material respects as of the date hereof, and shall survive the execution
of this Agreement (except to the extent such representations and warranties are made as of an earlier date in which case such
representations and warranties are true and correct in all material respects as of such earlier date).

 

    	 	2	 

     

    

 

		(b)	No event has occurred and is continuing that constitutes
a Default or an Event of Default.

 

		(c)	Borrower has all necessary power and authority to execute,
deliver, and perform in accordance with the terms thereof, this Agreement.

 

7.            Default.
Borrower’s failure to perform any covenant or other agreement contained in this Agreement or any other document entered into
pursuant hereto shall constitute an Event of Default under the Loan Agreement.

 

8.            Headings.
Headings in this Agreement are for convenience of reference only and are not part of the substance hereof.

 

9.            Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Connecticut without reference
to conflicts of law rules.

 

10.          Counterparts.
This Agreement may be executed in any number of counterparts, including by electronic or facsimile transmission, each of which
when so delivered shall be deemed an original, but all such counterparts taken together shall constitute but one and the same instrument.

 

11.          Integration.
This Agreement and the Loan Documents constitute and contain the entire agreement of Borrower and Lender with respect to their
respective subject matters, and supersede any and all prior agreements, correspondence and communications.

 

[Remainder of page intentionally
blank. Signature page follows.]

 

    	 	3	 

     

    

 

IN WITNESS WHEREOF, Borrower and Lender
have caused this SECOND AMENDMENT OF VENTURE LOAN AND SECURITY AGREEMENT to be executed as of the day and year first above written.

 

	 	BORROWER:
	 	 
	 	INTERLEUKIN GENETICS, INC.
	 	 
	 	By:	/s/ March Carbeau
	 	 
	 	Name: Mark Carbeau
	 	 
	 	Title: Chief Executive Officer

 

	 	LENDER:
	 	 
	 	HORIZON CREDIT II LLC
	 	 	 
	 	By: 	/s/ Robert D. Pomeroy
	 	 	Robert D. Pomeroy, Jr.
	 	 	Chief Executive Officer

 

[Signature page to Second Amendment of Venture
Loan and Security Agreement]

 

    	 	 	 

     

    

 

EXHIBIT A

 

Second Amended and Restated Secured Promissory
Note

 

(See attached)

 

    	 	 	 

     

    

 

SECOND AMENDED AND RESTATED SECURED PROMISSORY
NOTE

 

(Loan A)

 

	$5,000,000.00	Originally Dated:  December 23, 2014

 

Amended and Restated as of August 1, 2016

 

Second Amended and Restated as of April 1,
2017

 

FOR VALUE RECEIVED, the undersigned, INTERLEUKIN
GENETICS, INC., a Delaware corporation (“Borrower”), HEREBY PROMISES TO PAY to HORIZON CREDIT II LLC, a Delaware
limited liability company, as assignee of HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation (“Lender”)
the principal amount of Five Million Dollars and 00/100 ($5,000,000.00) or such lesser amount as shall equal the outstanding principal
balance of Loan A (the “Loan”) made to Borrower by Lender pursuant to the Loan Agreement (as defined below),
and to pay all other amounts due with respect to the Loan on the dates and in the amounts set forth in the Loan Agreement. This
Note amends, replaces and supersedes, in its entirety, that certain Amended and Restated Secured Promissory Note issued by Borrower
to Horizon Credit II LLC on August 1, 2016 (the “Original Note”). Nothing contained herein shall be deemed to
be a repayment or a novation of the Original Note.

 

Interest on the principal amount of this
Note from the date of this Note shall accrue at the Loan Rate or, if applicable, the Default Rate, each as established in accordance
with the Loan Agreement (as defined below). Interest shall be computed on the basis of a 360-day year for the actual number of
days elapsed. If the Funding Date is not the first day of the month, interim interest accruing from the Funding Date through the
last day of that month shall be paid on the first calendar day of the next calendar month. Commencing February 1, 2015 through
and including April 1, 2016, on the first day of each month (each an “Initial Interest Payment Date”) Borrower
shall make payments of accrued interest only on the outstanding principal amount of the Loan.

 

Commencing on May 1, 2016, and continuing
through July 1, 2016, on the first day of each month (each an “Initial Principal and Interest Payment Date”),
Borrower shall make to Lender an equal payment of principal in the amount of One Hundred Sixty-Six Thousand Six Hundred Sixty-Six
and 67/100 Dollars ($166,666.67) plus accrued interest on the then outstanding principal amount due hereunder.

 

Commencing August 1, 2016 through and including
December 1, 2016, on the first day of each month (each a “One-Third Principal and Interest Payment Date”) Borrower
shall make to Lender an equal payment of principal in the amount of Fifty-Five Thousand and 00/100 Dollars ($55,000.00) plus accrued
interest on the then outstanding principal amount due hereunder.

 

Commencing January 1, 2017 through and including
March 1, 2017, on the first day of each month (each a “Full Principal and Interest Payment Date”) Borrower shall
make to Lender an equal payment of principal in the amount of One Hundred Ninety-Two Thousand Forty-Five and 45/100 Dollars ($192,045.45)
plus accrued interest on the then outstanding principal amount due hereunder.

 

    	 	 	 

     

    

 

Commencing April 1, 2017 through and including
June 1, 2017, on the first day of each month (each an “Additional Interest Payment Date”), Borrower shall make
payments of accrued interest only on the outstanding principal amount of the Loan.

 

If Borrower meets the Extended Additional
Interest Only Milestone (as defined below), commencing July 1, 2017 through and including the earlier of (i) September 1, 2017
and (ii) the first day of the month following the Cash Infusion Date (as defined below), on the first day of each month (each an
“Additional Interest Payment Date”), Borrower shall make payments of accrued interest only on the outstanding
principal amount of the Loan.

 

Commencing on the earlier of (i) July 1,
2017, if Borrower does not satisfy the Extended Additional Interest Only Milestone, or (ii) the first day of the month following
the Cash Infusion Date and continuing on the first day of each month thereafter, Borrower shall make six (6) monthly payments of
principal in the amount of Two Hundred Thousand and 00/100 Dollars ($200,000.00) plus accrued interest on the then outstanding
principal amount due hereunder (each a “$200,000 Principal Payment Date”).

 

“Extended Additional Interest Only
Milestone” means, Borrower, on or before June 15, 2017, provides Lender with evidence reasonably satisfactory to Lender
that Borrower is negotiating the terms of a clinical services agreement with an entity that is not an Affiliate (as defined in
the Loan Agreement) of Borrower, which clinical services agreement (i) is on terms acceptable to Horizon, and (ii) will be, in
the good faith judgment of Borrower, executed on or prior to September 1, 2017.

 

“Cash Infusion Date”
means the first day of the month immediately following Borrower’s receipt of cash proceeds in an aggregate amount of not
less than One Million Five Hundred Thousand Dollars ($1,500,000) from any source, including, without limitation, revenue, up-front
payments, the sale of Equity Securities, or the issuance of subordinated promissory notes.

 

Commencing on the first day of the month
immediately following the last $200,000 Principal Payment Date, and continuing on the first day of each month through October 1,
2018 (each, a “Subsequent Principal and Interest Payment Date”, and together with each Initial Interest Payment
Date, each Initial Principal and Interest Payment Date, each One-Third Principal and Interest Payment Date, each Full Principal
and Interest Payment Date, each Additional Interest Payment Date, each Extended Additional Interest Only Payment Date, and each
$200,000 Principal Payment Date, each, a “Payment Date”), Borrower shall make to Lender equal payments of principal
in an amount sufficient to fully repay the Loan on or prior to October 1, 2018, plus accrued interest on the then outstanding principal
amount due hereunder.

 

On the earliest to occur of (i) October
1, 2018, (ii) payment in full of the principal balance of the Loan, or (iii) an Event of Default and demand by Lender of payment
in full of the Loan, Borrower shall make a payment of Three Hundred Twenty-Five Thousand and 00/100 Dollars ($325,000.00) to Lender
(the “Final Payment”). If not sooner paid, all outstanding amounts hereunder and under the Loan Agreement shall
become due and payable on October 1, 2018.

 

    	 	 	 

     

    

 

Principal, interest and all other amounts
due with respect to the Loan, are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement.
The principal amount of this Note and the interest rate applicable thereto, and all payments made with respect thereto, shall be
recorded by Lender and, prior to any transfer hereof, endorsed on the grid attached hereto which is part of this Note.

 

This Note is referred to in, and is entitled
to the benefits of, the Venture Loan and Security Agreement dated as of the date hereof (the “Loan Agreement”),
among Borrower and Lender. The Loan Agreement, among other things, (a) provides for the making of a secured Loan to Borrower, and
(b) contains provisions for acceleration of the maturity hereof upon the happening of certain stated events.

 

This Note may not be prepaid, except as
set forth in Section 2.3 of the Loan Agreement.

 

This Note and the obligation of Borrower
to repay the unpaid principal amount of the Loan, interest on the Loan and all other amounts due Lender under the Loan Agreement
is secured under the Loan Agreement.

 

Presentment for payment, demand, notice
of protest and all other demands and notices of any kind in connection with the execution, delivery, performance and enforcement
of this Note are hereby waived.

 

Borrower shall pay all reasonable fees and
expenses, including reasonable attorneys’ fees and costs, incurred by Lender in the enforcement or attempt to enforce any
of Borrower’s obligations hereunder not performed when due.

 

Any reference herein
to Lender shall be deemed to include and apply to every subsequent holder of this Note. Reference is made to the Loan Agreement
for provisions concerning optional and mandatory prepayments, Collateral, acceleration and other material terms affecting this
Note.

 

This Note shall be governed by and construed
under the laws of the State of Connecticut. Borrower agrees that any action or proceeding brought to enforce or arising out of
this Note may be commenced in the state or federal courts located within the State of Connecticut.

 

[Remainder of page intentionally blank.
Signature page follows.]

 

    	 	 	 

     

    

 

IN WITNESS WHEREOF, Borrower has caused
this Note to be duly executed by one of its officers thereunto duly authorized on the date hereof.

 

	 	BORROWER:
	 	 
	 	INTERLEUKIN GENETICS, INC.
	 	 
	 	By:	 
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 

 

    	 	 	 

     

    

 

EXHIBIT B

 

Form of Warrant

 

(See attached)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]